CA-TIGO
23.1.2024 15:01:31 CET | Business Wire | Press release
Tigo Energy, Inc. (NASDAQ: TYGO), a leading provider of intelligent solar and energy storage solutions, today announced the launch of the Tigo GO EV Charger for the German market. A smart charging station for electric vehicles, GO EV Charger offers seamless integration with the Tigo EI Residential solar-plus-storage solution. Available as both a single and three-phase charger up to 22 kW, the GO EV Charger can be wall-mounted indoors or outdoors and includes RFID technology for easy user authentication. With flexible charging modes tailored to accommodate homeowner use cases, the GO EV Charger can be installed and connected to the Tigo EI Inverter in minutes and managed centrally from the Tigo EI monitoring platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240123262185/en/
Available to the German market as a single and three-phase charger, the GO EV Charger offers flexible charging and easy management, tailored to accommodate each homeowner’s unique use case. (Photo: Business Wire)
“The synergy achieved by the integration of the charger with the solar-plus-storage solution marks a significant milestone in the journey towards a future of holistic residential energy systems,” said Klaus Besier, Managing Director at Germany’s Elektrobau Meffert GmbH, one of the first GO EV Charger customers. “As a PV installer, I believe it is crucial to have a comprehensive solution where the components are designed to work together seamlessly for an expeditious installation process. When you add the outstanding Tigo support team, which speaks the installer’s language, and the EI monitoring platform that empowers system owners to match solar energy production with their specific needs proactively, you have a winning combination. Tigo streamlines our ability to deliver more efficient and cohesive systems to more customers.”
With GO EV Charger, the Tigo EI Residential solution provides an efficient renewable energy ecosystem capable of generating, converting, storing, and managing solar energy from the roof down to the everyday needs of homeowners. On the web or through the Tigo EI App, Tigo provides homeowners with sophisticated management tools, and the Tigo Energy Intelligence platform serves as the central management platform for installers to monitor and manage the systems in their portfolios.
“Tigo’s journey first started with technological innovations to make solar safer and more efficient, followed by technologies that increase solar production and reduce operating costs as well as power conversion and energy storage, and the GO EV Charger is a natural next step in this evolution,” said Massimo Migliorini, Director Business Development EMEA – EI at Tigo Energy. “Homeowners have the capacity not only to generate clean and sustainable energy but to intelligently manage, store, and use it in once unimaginable ways. This milestone exemplifies Tigo’s unwavering commitment to renewable energy and giving individuals the power to actively contribute to a cleaner, greener future.”
The release of the GO EV Charger comes on the heels of an introductory webinar scheduled for February 5th. This will be followed by digital and live training events for German PV professionals, hosted with Tigo distribution partners in Germany between February and March. Additionally, the training offered by Tigo Academy – also available in German – will be enhanced by a series of technical content dedicated to the new Tigo solution for e-mobility.
For GO EV Charger ordering information and to get connected with an experienced member of the Tigo team, visit tigoenergy.com/contacts.
About Tigo Energy
Founded in 2007, Tigo is a worldwide leader in the development and manufacture of smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Tigo combines its Flex MLPE (Module Level Power Electronics) and solar optimizer technology with intelligent, cloud-based software capabilities for advanced energy monitoring and control. Tigo MLPE products maximize performance, enable real-time energy monitoring, and provide code-required rapid shutdown at the module level. The company also develops and manufactures products such as inverters and battery storage systems for the residential solar-plus-storage market. For more information, please visit www.tigoenergy.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240123262185/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom